JAKARTA - The number of daily new cases of COVID-19 in Indonesia continues to increase and has crossed the 6,000 mark this week. Reporting from the COVID-19 Task Force page, for 3 consecutive days (July 26-28) there were 6,483, 6,438, and 6,353 new cases.
Former Director of the World Health Organization (WHO) Southeast Asia, Professor Dr. Tjandra Yoga Aditama asked for high vigilance in the case of the death of COVID-19 RI along with the addition of daily cases that soared in various parts of the world, including Indonesia.
"In the last few days, the number of patients who died has also increased to more than 10 people. The increase in the death rate due to COVID-19 has also occurred in other countries, such as Australia and Japan," he said in a webinar entitled "Breakthroughs for COVID-19 Handling Therapy in the World. " which was held online, Sunday, August 31 last.
In the same webinar, dr. Umar Wahid, Sp.P, Founder of the All-Indonesian Regional Hospital Association (ARSADA) said that although the transmission and death rates in Indonesia are quite low compared to other countries, Indonesia has not yet completed the war against COVID-19. Therefore, case-finding efforts through testing, contact tracing, treatment efforts, strict enforcement of health protocols, and medical research must be carried out.
"This is not only the responsibility of the government and health workers, but also researchers to suppress the spread of COVID-19 which continues to worry. In addition to maintaining health procedures, breakthroughs in the medical world are needed to deal with COVID-19 so that socio-economic activities are not disrupted," he added.
One of the breakthroughs that has proven effective in preventing COVID-19 is the Nitric Oxide Nasal Spray (NONS) formula which is able to kill various viruses including COVID-19 in the upper respiratory tract, and prevent the spread of the virus to the lungs which can worsen health conditions.
This is recognized by the world's leading health journal The Lancet Global Health, a journal that is an internationally trusted source of reference for knowledge about global health. The first and only portable medical device product in the world that uses NONS technology is the Enovid Nose Sanitizer developed by SaNOtize, a global pharmaceutical company from Canada.
Enovid has gone through a phase 3 clinical trial conducted in India on COVID-19 patients who experience mild symptoms and are classified as a group at increased risk of disease, are not vaccinated, are over 45 years old, and have one or more comorbidities.
VOIR éGALEMENT:
The result, Enovid can kill viruses in the nasal cavity as much as 93.7 percent within 24 hours and 99 percent within 48 hours. This clinical trial also found no significant side effects so it is safe and well tolerated by patients.
Enovid is a breakthrough in the treatment of COVID-19. Its portable form is equipped with dual chamber technology that can produce nitric oxide with the right formulation when sprayed into the nose so that the quality is maintained.
"Enovid is easily accessible by the public and can be carried anywhere to prevent transmission of various viruses, including COVID-19," said Dr. Gilly Regev, Ph.D. who is the Co-Founder and CEO of SanNOtize.
"It is SaNOtize's vision to become part of the daily lives of the world's people in improving their health and quality of life, one of which is through the development of nitric oxide-based therapies," he added.
The existence of Enovid helps people to protect themselves from COVID-19 more easily. In Indonesia, Enovid can be obtained at various leading pharmacies and e-Commerce platforms Shopee and Tokopedia, making it easy to get.
The English, Chinese, Japanese, Arabic, and French versions are automatically generated by the AI. So there may still be inaccuracies in translating, please always see Indonesian as our main language. (system supported by DigitalSiber.id)